Induction of antitumor immunity using bone marrow-generated dendritic cells

Angel Porgador, David Snyder, Eli Gilboa

Research output: Contribution to journalArticle

313 Citations (Scopus)

Abstract

We have previously shown that bone marrow-generated dendritic cells (DC) pulsed with a class 1-restricted peptide are potent inducers of CD8+ CTL. In the present study we have investigated whether bone marrow-generated DC are capable of inducing antitumor immunity. We show that a single immunization with DC pulsed with OVA peptide was highly effective in eliciting a protective immune response against a challenge with tumor cells expressing the OVA gene (E.G7-OVA), more so than immunization with irradiated E.G7-OVA cells, OVA peptide-pulsed RMA-S cells, or free OVA peptide mixed with adjuvant. The addition of free OVA protein to day 4 or day 7 bone marrow cultures, but not to day 9 mature DC, was also effective in eliciting CTL and engendering antitumor immunity, but was less effective than peptide-pulsed DC. Induction of CTL and antitumor immunity by bone marrow-generated DC pulsed with the class I-restricted OVA peptide correlated with the expression of syngeneic MHC class II molecules on the DC. This and the fact that induction of tumor immunity was dependent on CD4+ T cells suggest that in vivo priming of CTL and induction of antitumor immunity by bone marrow-generated DC also require the presentation of MHC class II-restricted epitopes and activation of CD 4+ T cells. This observation has potentially important implications to the use of peptide-pulsed DC in clinical immunotherapy.

Original languageEnglish
Pages (from-to)2918-2926
Number of pages9
JournalJournal of Immunology
Volume156
Issue number8
StatePublished - Apr 15 1996
Externally publishedYes

Fingerprint

Dendritic Cells
Immunity
Bone Marrow
Peptides
Immunization
T-Lymphocytes
Immunotherapy
Epitopes
Neoplasms
Genes

ASJC Scopus subject areas

  • Immunology

Cite this

Induction of antitumor immunity using bone marrow-generated dendritic cells. / Porgador, Angel; Snyder, David; Gilboa, Eli.

In: Journal of Immunology, Vol. 156, No. 8, 15.04.1996, p. 2918-2926.

Research output: Contribution to journalArticle

Porgador, Angel ; Snyder, David ; Gilboa, Eli. / Induction of antitumor immunity using bone marrow-generated dendritic cells. In: Journal of Immunology. 1996 ; Vol. 156, No. 8. pp. 2918-2926.
@article{86865dacb52942d194876cf7ece0e975,
title = "Induction of antitumor immunity using bone marrow-generated dendritic cells",
abstract = "We have previously shown that bone marrow-generated dendritic cells (DC) pulsed with a class 1-restricted peptide are potent inducers of CD8+ CTL. In the present study we have investigated whether bone marrow-generated DC are capable of inducing antitumor immunity. We show that a single immunization with DC pulsed with OVA peptide was highly effective in eliciting a protective immune response against a challenge with tumor cells expressing the OVA gene (E.G7-OVA), more so than immunization with irradiated E.G7-OVA cells, OVA peptide-pulsed RMA-S cells, or free OVA peptide mixed with adjuvant. The addition of free OVA protein to day 4 or day 7 bone marrow cultures, but not to day 9 mature DC, was also effective in eliciting CTL and engendering antitumor immunity, but was less effective than peptide-pulsed DC. Induction of CTL and antitumor immunity by bone marrow-generated DC pulsed with the class I-restricted OVA peptide correlated with the expression of syngeneic MHC class II molecules on the DC. This and the fact that induction of tumor immunity was dependent on CD4+ T cells suggest that in vivo priming of CTL and induction of antitumor immunity by bone marrow-generated DC also require the presentation of MHC class II-restricted epitopes and activation of CD 4+ T cells. This observation has potentially important implications to the use of peptide-pulsed DC in clinical immunotherapy.",
author = "Angel Porgador and David Snyder and Eli Gilboa",
year = "1996",
month = "4",
day = "15",
language = "English",
volume = "156",
pages = "2918--2926",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Induction of antitumor immunity using bone marrow-generated dendritic cells

AU - Porgador, Angel

AU - Snyder, David

AU - Gilboa, Eli

PY - 1996/4/15

Y1 - 1996/4/15

N2 - We have previously shown that bone marrow-generated dendritic cells (DC) pulsed with a class 1-restricted peptide are potent inducers of CD8+ CTL. In the present study we have investigated whether bone marrow-generated DC are capable of inducing antitumor immunity. We show that a single immunization with DC pulsed with OVA peptide was highly effective in eliciting a protective immune response against a challenge with tumor cells expressing the OVA gene (E.G7-OVA), more so than immunization with irradiated E.G7-OVA cells, OVA peptide-pulsed RMA-S cells, or free OVA peptide mixed with adjuvant. The addition of free OVA protein to day 4 or day 7 bone marrow cultures, but not to day 9 mature DC, was also effective in eliciting CTL and engendering antitumor immunity, but was less effective than peptide-pulsed DC. Induction of CTL and antitumor immunity by bone marrow-generated DC pulsed with the class I-restricted OVA peptide correlated with the expression of syngeneic MHC class II molecules on the DC. This and the fact that induction of tumor immunity was dependent on CD4+ T cells suggest that in vivo priming of CTL and induction of antitumor immunity by bone marrow-generated DC also require the presentation of MHC class II-restricted epitopes and activation of CD 4+ T cells. This observation has potentially important implications to the use of peptide-pulsed DC in clinical immunotherapy.

AB - We have previously shown that bone marrow-generated dendritic cells (DC) pulsed with a class 1-restricted peptide are potent inducers of CD8+ CTL. In the present study we have investigated whether bone marrow-generated DC are capable of inducing antitumor immunity. We show that a single immunization with DC pulsed with OVA peptide was highly effective in eliciting a protective immune response against a challenge with tumor cells expressing the OVA gene (E.G7-OVA), more so than immunization with irradiated E.G7-OVA cells, OVA peptide-pulsed RMA-S cells, or free OVA peptide mixed with adjuvant. The addition of free OVA protein to day 4 or day 7 bone marrow cultures, but not to day 9 mature DC, was also effective in eliciting CTL and engendering antitumor immunity, but was less effective than peptide-pulsed DC. Induction of CTL and antitumor immunity by bone marrow-generated DC pulsed with the class I-restricted OVA peptide correlated with the expression of syngeneic MHC class II molecules on the DC. This and the fact that induction of tumor immunity was dependent on CD4+ T cells suggest that in vivo priming of CTL and induction of antitumor immunity by bone marrow-generated DC also require the presentation of MHC class II-restricted epitopes and activation of CD 4+ T cells. This observation has potentially important implications to the use of peptide-pulsed DC in clinical immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0030584839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030584839&partnerID=8YFLogxK

M3 - Article

C2 - 8609412

AN - SCOPUS:0030584839

VL - 156

SP - 2918

EP - 2926

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -